Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2
03:47pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.
Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates
03:37pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.
Here's Why Income Investors Should Consider Buying This High-Yield Dividend Stock
03:00pm, Tuesday, 02'nd Aug 2022 The Motley Fool
Novartis is one of the most dominant pharma companies in the world.
Here's Why Income Investors Should Consider Buying This High-Yield Dividend Stock
11:00am, Tuesday, 02'nd Aug 2022
Novartis is one of the most dominant pharma companies in the world.
Valeo Pharma enters commercialization and supply agreement with Novartis Canada for two ophthalmic therapies
08:01am, Tuesday, 02'nd Aug 2022
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it has entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc for the Canadian commercialization of two innovative
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
05:59pm, Monday, 01'st Aug 2022 Zacks Investment Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
The Zacks Analyst Blog Highlights Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems
12:04pm, Monday, 01'st Aug 2022 Zacks Investment Research
Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems are part of Zacks top Analyst Blog.
Alnylam's Strategy Is Getting Bigger. Time to Buy?
09:31am, Saturday, 30'th Jul 2022 The Motley Fool
After decades of developing rare-disease drugs, this RNA pioneer will aim for much larger audiences.
Mark Cuban Says Americans Shouldn't Have To Pick Between Rent, Food Or Medicine
08:38pm, Friday, 29'th Jul 2022 Benzinga
Famed billionaire, entrepreneur and Dallas Maverick’s owner Mark Cuban thinks Americans shouldn’t have to pick between necessities such as food, medicine or rent.
And he’s provided a solutio
Top Analyst Reports for Novartis, Duke Energy & Boston Scientific
06:04pm, Friday, 29'th Jul 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Duke Energy Corporation (DUK), and Boston Scientific Corporation (BSX).
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2
03:01pm, Friday, 29'th Jul 2022 Zacks Investment Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.
6 High-Yield Dividend Aristocrats Perfect For What's Coming Next
10:45am, Thursday, 28'th Jul 2022 Seeking Alpha
Stagflation is already here, with the economy weakening quickly and inflation raging at 40-year highs. Read more about the 6 stagflation beating stocks here.
Incyte (INCY) to Report Q2 Earnings: What's in the Cards?
02:09pm, Tuesday, 26'th Jul 2022 Zacks Investment Research
Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.
The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie
10:21am, Monday, 25'th Jul 2022 Zacks Investment Research
J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off
12:22pm, Friday, 22'nd Jul 2022 Zacks Investment Research
J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.
